What Pentomer Retard Treats: Main Uses and Benefits

Pentomer Retard is primarily utilized within clinical settings to provide targeted symptomatic support for chronic conditions where poor circulation restricts blood flow to the extremities, focusing on easing patient discomfort and supporting functional stability. This medication is applied as a common intervention for circulation problems across therapeutic domains involving the symptomatic management of intermittent claudication and supportive use in cases of chronic venous leg ulcers.

Symptomatic Relief and Mobility

Pentomer Retard is relevant in conditions characterized by periods of heightened symptoms, specifically applied to ease the aching, cramping, and pain experienced in the legs during walking or exercise. This symptomatic assistance is used in conditions where symptoms are linked to organ-specific functional stress caused by chronic occlusive arterial disease. The medication contributes to improved comfort during these periods and helps patients cope more steadily with these physically limiting episodes. The medication is applied to assist in increasing the distance a patient can walk without experiencing pain, which supports general well-being and mobility.

Summary: Support for Mobility and Symptoms
Therapeutic Aim	Used to help increase the distance a patient can walk without pain in chronic arterial disease.
Symptom Focus	Used for managing symptoms related to physical discomfort like aching, cramping, and fatigue in the legs.
Clinical Context	Applied in scenarios where ongoing symptomatic support is needed for circulation problems.

Regulatory References

1. NIH MedlinePlus overview

Who can and cannot use Pentomer retard?

This section describes the population eligibility and non-eligibility rules for Pentomer retard (Pentoxifylline), based strictly on official regulatory labeling.

Contraindicated Populations (Absolute Non-Eligibility)

The use of Pentomer retard is absolutely contraindicated in patients with a known hypersensitivity to the active substance, Pentoxifylline, or any other Xanthine Derivatives (such as caffeine or theophylline). It must also not be used in patients with a history of recent cerebral hemorrhage or extensive retinal hemorrhage. Some international labels additionally list acute myocardial infarction and active peptic ulceration as contraindications.

Populations Requiring Conditional Use

Regulatory documents mandate caution and often require a dose reduction for patients with impaired renal function (Creatinine Clearance under 30 mL/min) or hepatic impairment due to the risk of active metabolite accumulation. Use in older adults also requires cautious dose selection due to the greater likelihood of decreased organ function.

Age and Reproductive Eligibility

Safety and effectiveness of Pentomer retard have not been established in pediatric patients (under 18 years) and its use is not recommended for this age group. For pregnancy, the drug is classified as Category C by the FDA, meaning it should be used only if the potential benefit outweighs the potential risk. Pentoxifylline is excreted in human milk, leading regulators to recommend a decision to discontinue nursing or discontinue the drug.

Interactions with other medicines and products

Interaction Scope

The official regulatory documents outline interactions across several medicinal product categories, including Anticoagulants, Platelet Aggregation Inhibitors, Antihypertensive Drugs, and specific CYP1A2 Inhibitors. Specific medicines named in regulatory information include Cimetidine, Ciprofloxacin, Fluvoxamine, Theophylline, and Warfarin. The mechanistic basis involves both pharmacokinetic interaction (CYP1A2 enzyme inhibition leading to increased plasma concentration) and pharmacodynamic interaction (additive effects on hemostasis and blood pressure).

Interaction-related restrictions include a formal prohibition: the drug is contraindicated in patients with known hypersensitivity to any xanthine derivatives.

Official Interaction Statements

• Co-administration with Anticoagulants (e.g., Vitamin K antagonists) is linked to postmarketing reports of increased anticoagulant activity and/or prolonged prothrombin time.
• The addition of the drug to therapy with Platelet Aggregation Inhibitors (e.g., Aspirin) is associated with an increased risk of bleeding events.
• Strong CYP1A2 inhibitors, such as Ciprofloxacin and Fluvoxamine, may increase systemic exposure to the drug. Cimetidine similarly increases the plasma concentration of Pentoxifylline and its primary metabolite.
• Co-administration with Meals is documented to increase the drug’s C max and AUC.
• Antihypertensive Drugs may result in an additive hypotensive effect.

Population-Specific Interaction Notes

Caution is noted for patients with Hepatic Impairment or Renal Impairment, as these conditions may increase the exposure to the drug and its active metabolites due to altered clearance.

Inhibition of Calcium Channels

Pentomer retard is a sustained-release formulation. The drug exerts its action by selectively inhibiting the L-type voltage-gated calcium channels (VGCCs) present on both vascular smooth muscle cells and cardiac myocytes. This selective interaction reduces the influx of extracellular calcium ions.

---

Vascular Smooth Muscle Effects

The resulting decrease in intracellular calcium concentration leads to a reduction in the activation of contractile proteins within vascular smooth muscle. This induces vasodilation, a physiological process that reduces peripheral vascular resistance.

---

Myocardial Effects and Oxygen Demand

In cardiac tissue, the inhibition of VGCCs also leads to a reduction in the rate of impulse generation (negative chronotropy) and a decrease in the force of muscular contraction (negative inotropy). Through these combined actions, Pentomer retard reduces myocardial oxygen demand.

The administration of Pentomer retard is standardized around a high-level oral administration protocol for the extended-release (retard) 400 mg tablet. The entire tablet must be swallowed whole with liquid and must not be crushed, chewed, or broken, a procedural constraint necessary to preserve the integrity of the extended-release formulation. Proper administration involves taking the tablet with or immediately after meals. Treatment is typically long-term, requiring a minimum of 8 weeks of consistent use before the full effect is assessed.

---

Standard Adult and Population-Specific Dosing

The medicine is generally prescribed in a daily, divided-dose frequency.

Dosing Regimen	Dose and Frequency
Usual Adult Dose	400 mg three times per day (TID)
Dose Reduction for Intolerance	400 mg twice per day (BID)

Specific high-level rules are defined for usage in certain populations. A dose reduction to, for example, 400 mg once a day (QD) is required for patients with severe renal impairment (CrCl < 30 mL/min). A similar caution and need for adjustment are noted for severe hepatic impairment. The use of Pentomer retard in the pediatric population is not authorized as safety and efficacy have not been established.

Research Evidence / Overview of Studies for Pentomer Retard

Evidence for Use in Symptomatic Intermittent Claudication

The clinical evaluation for this indication was conducted primarily through Randomized Controlled Trials (RCTs) and systematic reviews. Research examined the medicine for use in conditions characterized by functional limitations, specifically chronic occlusive arterial disease. Studies focused on outcomes related to physical discomfort, specifically two measures of walking capacity: Pain-Free Walking Distance (PFWD) and Total Walking Distance (TWD), measured during treadmill testing. Outcomes also monitored objective circulatory measures, such as the Ankle-Brachial Pressure Index (ABI).

Studies explored outcomes related to physical discomfort and reported that measured walking capacity varied across the findings when compared to placebo. Scientific reviews describe the evidence for these functional outcomes as consistently having a low certainty. Some trials reported that measured objective circulatory outcomes (ABI) and generalized quality of life scores were often similar to those observed with placebo. Research highlights the presence of high heterogeneity (inconsistent results) between the pooled trials, which complicated the overall interpretation of findings.

Evidence for Use in Chronic Venous Leg Ulcers

For chronic venous leg ulcers, clinical investigation was evaluated in controlled trials and meta-analyses. The research explored outcomes related to systemic or functional imbalance and the resulting skin changes. Studies monitored primary healing measures, including the proportion of participants achieving complete ulcer epithelialization (healing) and measured reductions in ulcer size. Outcomes describing episodic or acute changes were also examined, such as patient-reported intensity of pain.

Systematic reviews described research where a higher proportion of complete ulcer healing was reported compared to placebo, particularly when used in studies alongside standard care. These measurements taken from trials are generally summarized as providing moderate-level evidence for the healing outcome. Findings describe group patterns observed in studies exploring short-term symptom changes, primarily related to scenarios where the medicine was evaluated in an adjunctive role (in addition to) established therapies like compression bandaging.

Evidence Quality and Uncertainty

The overall certainty remains low for outcomes related to walking capacity in claudication due to mixed findings and high heterogeneity across studies. The evidence quality varies across the trials. Key limitations include the fact that follow-up durations were limited across many trials, and sample sizes were modest in some of the older studies. The long-term effects are not fully established; the assessment of long-term functional outcomes and data beyond approximately one year remain insufficient. Research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes.

Common questions about Pentomer retard (FAQ)

Q: Is Pentomer retard a type of blood thinner or anticoagulant?

Official product information classifies Pentomer retard (pentoxifylline) as a hemorheologic agent, which affects the flow properties of blood by reducing its viscosity and enhancing red blood cell flexibility. It is not formally classified as a blood thinner, but official documents note that it interacts with medicines in the anticoagulant and antiplatelet categories.

Q: Why is the drug called "Pentomer retard"?

The active ingredient is Pentoxifylline. The brand name includes the term "retard" because the tablet is manufactured as an extended-release formulation. This specialized design ensures the medicine releases its contents slowly into the body to maintain a steady therapeutic level over a sustained duration.

Q: Can Pentomer retard interact with common over-the-counter pain relievers?

Official regulatory documents indicate that co-administration with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), a class that includes many common over-the-counter pain relievers, has been linked to reports of bleeding events. Because of this potential for additive effects, caution and monitoring is required when Pentomer retard is used alongside NSAIDs.

Q: Is Pentomer retard safe for people with a history of heart problems?

Official information advises that the medication should be used with caution and close monitoring is recommended for patients who have concurrent heart or cerebrovascular conditions. This is due to potential side effects noted in regulatory documents, such as hypotension or changes in heart rhythm.

Q: Do I need to follow a special diet while taking Pentomer retard?

The official product information states that the tablet should be administered with or immediately after meals, as this is a condition required for proper use, absorption, and tolerance. Beyond this meal timing requirement, regulatory documents do not specify any special restrictive diet.

Q: How long does the 'retard' or slow-release effect last in the body?

The extended-release (retard) formulation is specifically designed to eliminate peaks and troughs in plasma levels, maintaining a relatively constant concentration of the drug and its active metabolites in the bloodstream. This is intended to prevent sharp rises and drops in drug levels and sustain the therapeutic effect over an extended time.

Q: Are there any known allergic reactions to the non-active ingredients in Pentomer retard?

The official patient information requires a disclosure of any known allergies to the active substance, related compounds (xanthine derivatives), or other substances such as medications, foods, dyes, or preservatives. This is necessary to assess the risk of allergic reactions to all components of the tablet.

Q: Can Pentomer retard be prescribed to both men and women for the same uses?

Yes, the official prescribing information provides dosing and indication for the general 'Adult' population without distinguishing based on gender. The medicine is used to treat conditions like intermittent claudication in both men and women.

Q: Is there a generic version of Pentomer retard available?

Yes. Official product information confirms that the active ingredient in Pentomer retard is Pentoxifylline, and generic extended-release tablets containing this ingredient are available.

Q: What happens if I miss a scheduled dose of Pentomer retard?

Official patient instructions describe a protocol for a missed dose: the dose is typically taken as soon as it is remembered unless it is near the time for the next scheduled dose, in which case the missed dose is skipped. The guidance explicitly prohibits taking double or extra doses.

Q: What should I know about taking Pentomer retard with herbal supplements?

The official label requires disclosure to the prescribing physician about the use of any herbal products or supplements. This is necessary because certain supplements may pose a risk of increased bleeding when combined with this medication.

Q: Is Pentomer retard used to treat deep vein thrombosis (DVT)?

Official regulatory bodies, such as the FDA, have approved this medication for the symptomatic treatment of intermittent claudication, which is a condition involving chronic occlusive arterial disease. This approved use does not include the treatment of deep vein thrombosis (DVT).

Q: Are there known interactions between Pentomer retard and antacids?

Yes, official patient instructions note that co-administration with an antacid has been associated with helping to lessen the chance of experiencing stomach upset.

Q: What if I accidentally take more than the prescribed amount of Pentomer retard?

Official patient safety information lists potential signs of an overdose, which may include drowsiness, flushing, faintness, unusual excitement, and convulsions (seizures). Regulatory guidance dictates that if an overdose is suspected, immediate contact with a poison control center or emergency room is required.

Q: Are there any restrictions on driving or operating machinery while on Pentomer retard?

Official regulatory warnings state that the medicine may cause dizziness or affect coordination. Restrictions apply to driving or operating machinery until the individual is certain how the medication affects their alertness and coordination.

Q: What foods or drinks should be limited while taking Pentomer retard?

Official product information states that there are no known interactions between the medication and foods or drinks that require patients to follow specific dietary restrictions.

Q: Can Pentomer retard be taken with common mineral supplements like iron?

Official patient information requires the disclosure of all mineral supplements being used. This is relevant because studies have explored the drug's potential impact on iron metabolism in specific patient populations.

Q: Does Pentomer retard affect blood sugar levels?

Official prescribing information indicates that this medication is known to interact with antidiabetic agents. Due to this potential interaction, use with caution is advised for individuals using medicines to manage blood sugar.

Q: Is Pentomer retard prescribed for conditions like Raynaud's phenomenon?

The FDA-approved indication for this medication is specifically for the symptomatic treatment of intermittent claudication due to chronic occlusive arterial disease of the limbs. Raynaud's phenomenon is not included in the official approved indications.

How to Store and Dispose of Pentomer retard

Official labeling defines strict conditions for storing and disposing of Pentomer retard (Pentoxifylline extended-release) to maintain its stability and effectiveness.

Storage and Protection Requirement	Official Instruction
Temperature	Store below 25°C (77°F); Do not freeze.
Environment	Protect from light, moisture, and excess heat.
Container	Keep in the original container, tightly closed.
Child Safety	Keep out of the sight and reach of children.

The medicine must not be taken after the expiration date printed on the package. Disposal of unused or expired Pentomer retard must be carried out in accordance with local regulations for pharmaceutical waste, and the product should not be disposed of in household trash or wastewater.